Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-12-31
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect
NCT02097758
A Multicenter Randomized Controlled Trial of Echocardiography-Guided Atrial Septal Defect Closure Performed in a Mobile Surgical Unit
NCT07273227
Electrocardiographic and Electrophysiologic Changes After Percutaneous Closure of Atrial Septal Defect
NCT06761807
CliNical Study on UltrasOund-guided Percutaneous InterVention for AtriAl Septal Defect With the Assistance of Specialized Instruments
NCT07054541
Outcomes of Transcatheter Aortic Valve Implantation in Management of Severe Symptomatic Aortic Stenosis
NCT03633383
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For all patients the following study tools will be done:
1. Written consent.
2. Detailed history including Age, sex, symptoms (NYHA class).
3. Clinical examination.
4. Electrocardiogram (ECG) (to detect baseline rhythm).
5. Two-dimensional transthoracic echocardiography (2D TTE):
All patients will undergo 2D TTE before device closure to assess:
* ASD (type, size, shunt direction).
* Pulsed Doppler quantification of the pulmonary (Qp) to systemic (Qs) blood flow ratio
* Right ventricle (RV) enlargement: RV linear dimensions are best measured from a RV-focused apical four-chamber view.
* RV systolic function by :
1. Tricuspid annular plane systolic excursion(TAPSE) ,
2. 2D RV fractional area change (FAC)= 100 X \[(end-diastolic area - end-systolic area)/end-diastolic area)\].
* Pulmonary artery systolic pressure (PASP).
* Grade of MR by Color Doppler: The color Doppler jet area of MR and left atrial area at the time of midsystole will be measured by the area trace method in the apical 4-chamber view, and the ratio of MR jet area to left atrial area will be calculated. The grade of MR will be determined by the ratio, where 0% to 10%\>\> none/trivial, 10% to 20% \>\> mild, 20% to 40% \>\>moderate, and \>40% \>\> severe.
* Left ventricle (LV) systolic function by m-mode,
* LV diastolic function :
1. Pulsed wave (PW) Doppler of trans-mitral flow during diastole.
2. Tissue Doppler imaging (TDI).
6. Three-dimensional transesophageal echocardiography (3D-TEE):
All patients will undergo 3D-TEE before device closure of secundum ASD to assess:
1. The number of defects.
2. Defect size: The maximum dimension (length), minor dimension (width), and area by planimetry will be measured from the 3D en face view.
3. ASD morphology will be categorized by the shape seen in the en face view. ASD will be defined as circular when the minor dimension is \>75% of the maximum length. If the minor dimension is \<75% of the maximum length ASD will be defined as having an oval shape. Asymmetric, irregularly shaped defects that are not elliptical will be defined as having a complex shape.
4. The surrounding rims: aortic rim, atrioventricular (AV) rim, superior vena cava (SVC) rim, inferior vena cava (IVC) rim and posterior rim.
According to recent study, the optimal ASD device size will be calculated as :
Device size = 0.964 x 3Dmax - 2.622 x circular index +7.084 Where maximal ASD diameter on 3D-TEE (3Dmax) and the circular index is defined as the ratio of the maximal to minimal diameters on the 3D-TEE image.
7. Transcatheter secundum ASD device closure procedure:
All patients suitable for device closure will undergo transcatheter device closure procedure in cath lab under general anesthesia. After venous access is gained following local anesthesia via the right femoral vein, the ASD is crossed using a Multipurpose catheter. The Multipurpose catheter is then exchanged for a device-specific delivery system. Its tip is placed into the left atrium. The left-sided disk is then deployed and gently pulled back against the atrial septum under fluoroscopic guidance in a left anterior oblique projection. To deploy the right atrial disc, tension is maintained on the delivery cable while the delivery sheath is further withdrawn.
The whole procedure will be under fluoroscopic and 3D-TEE guidance. Device size that will be used in ASD closure according to the previously mentioned formula based on 3D-TEE measurements.
8. Follow up:
* Clinical follow up for 24 hours to detect post-ASD closure acute heart failure.
* 2D-TTE will be performed 24 hours post-procedure to visualize the device position and to look for residual shunting and MR grade using color Doppler.
* Clinical follow up, ECG and 2D-TTE at 6-month follow up to detect new onset AF, residual shunt and MR deterioration.
9. After 6 months of device closure :
Patients will be divided into two groups according to occurrence of adverse outcomes (residual shunt , MR deterioration and new onset AF ) and the following predictors will be evaluated in each group and their influence on occurrence of these adverse outcomes:
Echocardiographic data:
* RV systolic function by TAPSE and FAC on 2D-TTE.
* LV systolic function by m-mode on 2D-TTE.
* LV diastolic function on 2D-TTE.
* Estimated PASP on 2D-TTE.
* ASD shape on 3D-TEE.
* ASD maximal diameter on 3D-TEE.
* ASD minimal diameter on 3D-TEE.
* ASD area on 3D-TEE.
* Size of implanted device.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with residual shunt
patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
ASD device closure
transcatheter secundum ASD device closure
patients without residual shunt
patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
ASD device closure
transcatheter secundum ASD device closure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ASD device closure
transcatheter secundum ASD device closure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Impaired functional capacity.
2. Right atrial and/or RV enlargement.
3. Left-to-right shunt with \[Qp: Qs\] ≥1.5:1.
4. Paradoxical embolism.
* Patients with isolated secundum ASD with sufficient rims suitable for device closure.
Exclusion Criteria
* A single defect too large for closure (\>38 mm)
* Multiple ASDs unsuitable for percutaneous closure.
* Anterior, posterior, superior, or inferior rim \<5 mm.
* Abnormal pulmonary venous drainage.
* Associated structural heart disease requiring cardiac surgery.
* ASD with severe pulmonary arterial hypertension and bidirectional or right-to-left shunting.
* Intracardiac thrombi diagnosed by echocardiography.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Aboelkasem Ali Mousa
Assistant lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed Mousa
Role: PRINCIPAL_INVESTIGATOR
Assiut University
References
Explore related publications, articles, or registry entries linked to this study.
Alnasser S, Lee D, Austin PC, Labos C, Osten M, Lightfoot DT, Kutty S, Shah A, Meier L, Benson L, Horlick E. Long term outcomes among adults post transcatheter atrial septal defect closure: Systematic review and meta-analysis. Int J Cardiol. 2018 Nov 1;270:126-132. doi: 10.1016/j.ijcard.2018.06.076. Epub 2018 Jul 12.
Villablanca PA, Briston DA, Rodes-Cabau J, Briceno DF, Rao G, Aljoudi M, Shah AM, Mohananey D, Gupta T, Makkiya M, Ramakrishna H, Garcia MJ, Pass RH, Peek G, Zaidi AN. Treatment options for the closure of secundum atrial septal defects: A systematic review and meta-analysis. Int J Cardiol. 2017 Aug 15;241:149-155. doi: 10.1016/j.ijcard.2017.03.073. Epub 2017 Mar 24.
Silvestry FE, Cohen MS, Armsby LB, Burkule NJ, Fleishman CE, Hijazi ZM, Lang RM, Rome JJ, Wang Y; American Society of Echocardiography; Society for Cardiac Angiography and Interventions. Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J Am Soc Echocardiogr. 2015 Aug;28(8):910-58. doi: 10.1016/j.echo.2015.05.015. No abstract available.
Chessa M, Carminati M, Butera G, Bini RM, Drago M, Rosti L, Giamberti A, Pome G, Bossone E, Frigiola A. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol. 2002 Mar 20;39(6):1061-5. doi: 10.1016/s0735-1097(02)01711-4.
Rao PS, Langhough R. Relationship of echocardiographic, shunt flow, and angiographic size to the stretched diameter of the atrial septal defect. Am Heart J. 1991 Aug;122(2):505-8. doi: 10.1016/0002-8703(91)91008-b.
Gupta SK, Sivasankaran S, Bijulal S, Tharakan JM, Harikrishnan S, Ajit K. Trans-catheter closure of atrial septal defect: Balloon sizing or no Balloon sizing - single centre experience. Ann Pediatr Cardiol. 2011 Jan;4(1):28-33. doi: 10.4103/0974-2069.79619.
Kong WK. The relation between atrial septal defect area, diameter and shape using balloon sizing and three-dimensional transoesophageal echocardiography during percutaneous closure using occlutech device. Journal of the American College of Cardiology. 2017;69(11 Supplement):1493.
Scacciatella P, Marra S, Pullara A, Conrotto F, Marchetti M, Ferraro G, Pavani M, Biasco L, Bongiovanni D, Gaita F, Orzan F. Percutaneous closure of atrial septal defect in adults: very long-term clinical outcome and effects on aortic and mitral valve function. J Invasive Cardiol. 2015 Jan;27(1):65-9.
Akagi T, Fujii Y, Takaya Y, Takahashi S, et al. Clinical benefit of transcatheter closure for newly developed atrial fibrillation in adult patients with atrial septal defect. Journal of the American College of Cardiology. 2018;71(11):A549.
Takaya Y, Kijima Y, Akagi T, Nakagawa K, Oe H, Taniguchi M, Sano S, Ito H. Fate of Mitral Regurgitation After Transcatheter Closure of Atrial Septal Defect in Adults. Am J Cardiol. 2015 Aug 1;116(3):458-62. doi: 10.1016/j.amjcard.2015.04.042. Epub 2015 May 7.
Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Apr 2;73(12):e81-e192. doi: 10.1016/j.jacc.2018.08.1029. Epub 2018 Aug 16. No abstract available.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010. No abstract available.
Johri AM, Witzke C, Solis J, Palacios IF, Inglessis I, Picard MH, Passeri JJ. Real-time three-dimensional transesophageal echocardiography in patients with secundum atrial septal defects: outcomes following transcatheter closure. J Am Soc Echocardiogr. 2011 Apr;24(4):431-7. doi: 10.1016/j.echo.2010.12.011. Epub 2011 Jan 22.
Jang JY, Heo R, Cho MS, Bae J, Hong JA, Lee S, Ahn JM, Park DW, Kim DH, Kang DH, Song JK, Song JM. Efficacy of 3D transoesophageal echocardiography for transcatheter device closure of atrial septal defect without balloon sizing. Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):684-689. doi: 10.1093/ehjci/jex153.
WINDECKER S, MEIER B. Percutaneous closure of patent foramen ovale, atrial septal defects and the left atrial appendage. Essential Interventional Cardiology (Second Edition): Elsevier; 2008. p. 449-68.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASD closure guided by 3D-TEE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.